Summary
Haematological malignancies, also known as blood cancers, are a diverse and complex group of diseases that are difficult to diagnose and treat. Nowadays most treatments are extremely complex, and advances in patient diagnosis and treatment are slow due to the low number of patients per centre. There is therefore a need to harmonise, store, and analyse the current information on these diseases to speed up and support the decision-making process for patient access to new therapies.
IMI’s HARMONY project is using big data to advance our understanding of the following seven blood cancers: acute lymphoblastic leukaemia (ALL); acute myeloid leukaemia (AML); chronic lymphocytic leukaemia (CLL); multiple myeloma (MM); myelodysplastic syndromes (MDS); non-Hodgkin lymphoma (NHL); and paediatric haematologic malignancies. HARMONY has set up a Big Data platform to support its work.
The aim of HARMONY PLUS is to build on HARMONY’s work. Firstly, it will add the following blood cancers to the list of diseases under study: chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; as well as Hodgkin’s lymphoma, Waldenström macroglobulinemia and other rare blood cancers not covered by HARMONY.
In addition, HARMONY PLUS will help to convert the existing HARMONY platform into an integrated services platform that could serve clinicians to improve their decision making process and support clinical trial design, among other things.
Like HARMONY, HARMONY PLUS is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others.
Achievements & News
September 2022
IMI project HARMONY is proposing a new, more accurate way of assessing the prognosis of patients with multiple myeloma.
Participants
Show participants on mapEFPIA companies
- Abbvie Inc, North Chicago, Illinois, United States
- Bayer Aktiengesellschaft, Leverkusen, Germany
- Celgene Management SARL, Couvet, Switzerland
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Menarini Ricerche S.A, Pomezia, Italy
- Novartis Pharma AG, Basel, Switzerland
- Pfizer Limited, Sandwich, Kent , United Kingdom
Universities, research organisations, public bodies, non-profit groups
- Agencia Espanola De Medicamentos Y Productos Sanitarios, Madrid, Spain
- Alma Mater Studiorum - Universita Di Bologna, Bologna, Italy
- Bundesinstitut Fur Arzneimittel Und Medizinprodukte, Bonn, Germany
- Charite - Universitaetsmedizin Berlin, Berlin, Germany
- Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
- European Research Initiative On Cll Ev, Köln, Germany
- European Society For Blood And Marrow Transplantation, Leiden, Netherlands
- Fondazione Italiana Sindromi Mielodisplastiche Ets, Alessandria, Italy
- Fundacio Institut De Recerca Contra La Leucemia Josep Carreras, Barcelona, Spain
- Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon, Soria, Spain
- Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana, Valencia, Spain
- Genome Research Limited, London, United Kingdom
- Groupe Francophone Des Myelodysplasies, Paris, France
- Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
- Masarykova univerzita, Brno, Czech Republic
- National Institute For Health And Care Excellence, Manchester, United Kingdom
- Ospedale Pediatrico Bambino Gesu, Rome, Italy
- Stichting Amsterdam Umc, Amsterdam, Netherlands
- Stiftung Eln Foundation, Weinheim, Germany
- The Lymphoma Study Association, Pierre Benite, France
- Universidad De Navarra, Pamplona, Spain
- Universita Degli Studi Di Torino, Turin, Italy
- Universitaet Ulm, Ulm, Germany
- University Of Newcastle Upon Tyne, Newcastle upon Tyne, United Kingdom
- University of Cambridge, Cambridge, United Kingdom
- University of Helsinki, University of Helsinki, Helsinki, Finland
- Vib Vzw, Zwijnaarde - Gent, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- European Hematology Association, The Hague, Netherlands
- Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain
- Gpoh Gemeinnutzige GMBH, Hannover, Germany
- Mll Munchner Leukamielabor GMBH, Munich, Germany
- Synapse Research Management Partners SL, Barcelona, Spain
Patient organisations
- Leukanet Ev, Riemerling, Germany
Third parties
- Istituto Nazionale Di Fisica Nucleare, Frascati, Italy
- Lysarc, Pierre-Benite, France
| Participants | |
|---|---|
| Name | EU funding in € |
| Agencia Espanola De Medicamentos Y Productos Sanitarios | 75 750 |
| Alma Mater Studiorum - Universita Di Bologna | 239 000 |
| Bundesinstitut Fur Arzneimittel Und Medizinprodukte | 11 250 |
| Charite - Universitaetsmedizin Berlin | 335 250 |
| Erasmus Universitair Medisch Centrum Rotterdam | 90 000 |
| European Hematology Association | 664 250 |
| European Research Initiative On Cll Ev | 90 000 |
| European Society For Blood And Marrow Transplantation | 121 250 |
| Fondazione Italiana Sindromi Mielodisplastiche Ets | 90 000 |
| Fundacio Institut De Recerca Contra La Leucemia Josep Carreras | 90 000 |
| Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon | 1 606 368 |
| Fundacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana | 405 000 |
| Genome Research Limited | 54 000 |
| Gmv Soluciones Globales Internet Sau | 502 500 |
| Gpoh Gemeinnutzige GMBH | 90 000 |
| Groupe Francophone Des Myelodysplasies | 90 000 |
| Leukanet Ev | 276 125 |
| Ludwig-Maximilians-Universitaet Muenchen | 90 000 |
| Masarykova univerzita | 54 000 |
| Medisapiens Oy (left the project) | 32 632 |
| Mll Munchner Leukamielabor GMBH | 54 000 |
| National Institute For Health And Care Excellence | 328 500 |
| Ospedale Pediatrico Bambino Gesu | 90 000 |
| Stichting Amsterdam Umc | 90 000 |
| Stiftung Eln Foundation | 90 000 |
| Synapse Research Management Partners SL | 307 750 |
| The Lymphoma Study Association | 18 750 |
| Universidad De Navarra | 90 000 |
| Universita Degli Studi Di Torino | 90 000 |
| Universitaet Ulm | 90 000 |
| University of Cambridge | 90 000 |
| University of Helsinki | 54 000 |
| University Of Newcastle Upon Tyne | 90 000 |
| Vib Vzw | 54 000 |
| Third parties | |
| Name | Funding in € |
| Istituto Nazionale Di Fisica Nucleare | 100 000 |
| Lysarc | 71 250 |
| Total Cost | 6 715 625 |